Invention Grant
- Patent Title: Compound containing tricyclic heteroaryl group
-
Application No.: US16468810Application Date: 2017-12-12
-
Publication No.: US10730887B2Publication Date: 2020-08-04
- Inventor: Hancheng Zhang , Shifeng Liu , Xiangyang Ye
- Applicant: Hangzhou Innogate Pharma Co., Ltd.
- Applicant Address: CN Hangzhou, Zhejiang
- Assignee: Hangzhou Innogate Pharma Co., Ltd.
- Current Assignee: Hangzhou Innogate Pharma Co., Ltd.
- Current Assignee Address: CN Hangzhou, Zhejiang
- Agency: Panitch Schwarze Belisario & Nadel LLP
- Priority: com.zzzhc.datahub.patent.etl.us.BibliographicData$PriorityClaim@60f496a6
- International Application: PCT/CN2017/115756 WO 20171212
- International Announcement: WO2018/108084 WO 20180621
- Main IPC: C07D498/04
- IPC: C07D498/04 ; C07D471/04 ; A61P1/16 ; A61P35/00 ; A61K31/5383 ; C07D519/00 ; A61P11/00

Abstract:
A class of compounds containing a tricyclic heteroaryl group is provided. Specifically, a compound of the structure represented by the following formula (I) (each group is as defined in the specification), a pharmaceutical composition containing the compound of the formula (I), and their isotope derivatives, chiral isomers, allosterics, different salts, prodrugs, preparations, etc, are provided. It can effectively inhibit protein kinases (such as EGFR, FAK, SYK, FLT-3, Axl, CDK, JAK, etc.), thereby treating various tumors, non-alcoholic liver disease (NASH), pulmonary fibrosis (IPF), and related variety of diseases.
Public/Granted literature
- US20190308993A1 COMPOUND CONTAINING TRICYCLIC HETEROARYL GROUP Public/Granted day:2019-10-10
Information query